Pair Name | Ginseng polysaccharides, Anti-mouse PD-1 | ||
Phytochemical Name | Ginseng polysaccharides (PubChem CID: / ) | ||
Anticancer drug Name | Anti-mouse PD-1 (PubChem CID: / ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Ginseng polysaccharides, Anti-mouse PD-1 | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Immunomodulatory | |||
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
NCI-H460 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0459 | |
NCI-H1299 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0060 | |
In Vivo Model | Approximately 5×10⁵ Lewis lung cancer (LLC) cells and 5×104 B16-F10 cells were subcutaneously inoculated into the right flanks of mice. | |||
Result | These results demonstrate that GPs combined with αPD-1 mAb may be a new strategy to sensitise non-small cell lung cancer patients to anti-PD-1 immunotherapy. The gut microbiota can be used as a novel biomarker to predict the response to anti-PD-1 immunotherapy. |
No. | Title | Href |
---|---|---|
1 | Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. Gut. 2022;71(4):734-745. doi:10.1136/gutjnl-2020-321031. | Click |